Thus, in order to further improve the treatment strategy and management of resected NSCLC, we performed this updated meta-analysis to summarize the efficacy and safety of adjuvant EGFR-TKIs for patients with resected NSCLC based on updated data and new evidence. This evidence concerns the gene EGFR and non-small cell lung carcinoma.